Emma begins a trial of Depakine treatment

Emma begins a trial of Depakine while hospitalized at the PAAZ, after Rajid recognizes that her mood changes are far more frequent than the ordinary pattern he describes. The treatment is not presented as a cure or a clean turning point: it is a cautious medication change that requires further observation, brings physical side effects, and unfolds alongside Emma’s recurring depression and suicidal thoughts. Its significance lies in the tension between a clinical plan aimed at reducing mood swings and an illness that can make even survival feel briefly, then painfully, insufficient.

Background and Clinical Rationale

Rajid reviews Emma’s mood records and sees a pattern she has come to regard as normal. He explains that bipolar disorder does not usually mean patients are always depressed or hypomanic or manic: on average, he says, patients experience only three such episodes in ten years, with the rest of the time feeling normal. Emma answers that even three episodes a year would seem like a holiday compared with the three in a month she sometimes experiences. The contrast makes the difference between her lived baseline and the clinical comparison unmistakable.

Rajid had suspected the frequency from Emma’s file, though he had hoped it might have resulted chiefly from the pressure of her earlier hospitalization. He names the pattern rapid cycling and warns that this variant responds less well to treatment. The label gives a clinical shape to what Emma had treated as ordinary, but it also carries difficult implications: the problem is not only that her moods shift, but that the speed of those shifts may complicate treatment.

The medication discussion follows from that assessment. Rajid rules out antidepressants, explaining that they can turn ordinary bipolar depression into rapid cycling. He says that some medicines, combined with lithium, can reduce the duration and frequency of mood swings. Tegretol has already caused Emma adverse effects, so he proposes Depakine, another anti-epileptic drug with a somewhat different mechanism, to be added to lithium. The decision is a monitored trial rather than a prescription for immediate return home: Rajid wants Emma to remain at least two more weeks while the dose is increased, and possibly longer, so the team can see how she responds before sending her home on new medication.

Starting Depakine and Its Immediate Effects

The treatment begins on Sunday evening. When Emma later fits another piece into her puzzle, she notices that the side effects have started: her mouth is dry, her head hurts, and her hands tremble. These concrete discomforts mark the transition from a proposed treatment plan to a bodily experience, while the puzzle gives the scene its immediate setting and her hands a visible sign of the medication’s effects.

At first, Emma registers that she is still alive as a gain. But even as she thinks this, she knows that the thought no longer feels like a victory. Distraction, including working on the puzzle and concentrating on other people, lets her temporarily avoid the force of her despair; when the distraction falls away, she compares it to a thin sheet of ice over a deep, dark lake, liable to crack beneath her. The image describes the fragile reprieve without suggesting that Depakine itself caused the returning depression: the evidence records the physical side effects and the emotional collapse together, but does not establish that one produced the other.

The approaching visit from Sergei sharpens Emma’s fear of what emotional numbness has taken from her. She expects to hold his hand and feel nothing, because, as she understands it, the vast sorrow leaves no room for love. The puzzle’s final piece does not restore a sense of coherence. Emma does not recognize what the completed image represents; she lifts one corner and feels it crumble beneath her fingers. The scene sets an uncertain medication trial beside an experience of the self and its meanings coming apart.

The Illness the Trial Must Address

The treatment takes place against an established history of depression and suicide risk, not merely a newly observed fluctuation in mood. When Rajid asks what she felt around the time of her admission, Emma recalls having no emotional response when told that Doctor Visser’s husband had died. She had known Doctor Visser as her psychiatrist for more than two years, yet felt nothing about the death or Doctor Visser’s absence. What she remembers instead is finding it absurd that Doctor Visser had children. Emma describes herself as having no room left for ordinary feeling because one enormous idea had absorbed her thoughts and emotions.

That idea was that she had to die. Emma recounts that, after months of depression, the conviction arrived while she was making breakfast the day before admission: it was time, she believed, to remove herself so she could get on with what mattered, especially work and productivity. In the moment, she did not experience this as a suicide plan carrying emotional weight; it seemed to her an inevitable instruction. That account helps explain why treatment and observation matter in this episode: Emma’s own interpretation of danger had not matched how grave the situation appeared to others.

Elsewhere in her account of depression, Emma describes the return of a memory associated with the balcony, against which she had been fighting during the night. She portrays depression as stripping away her energy until she is reduced to fragments clinging to life and drawn toward the depths beyond the balcony. This recurring image gives the medication episode a history and a threat, but does not turn it into a simple before-and-after story. The planned treatment begins while that history remains active.

Observation, Relationships, and Uncertain Progress

Rajid’s request that Emma remain in hospital shows the limits of what the trial can establish at its outset. He does not want to send her home with a new medicine before its effects are known, and he anticipates at least two more weeks of dose adjustment. Emma’s sense of home has become difficult to recover; the prospect of further hospitalization is therefore not a neutral interval, even as it provides a setting for medical monitoring.

Medication also carries meanings beyond its clinical purpose within the ward. In a conversation about Sergei’s reluctance to remove Emma’s stockpiled pills, Emma fears that his resistance means he does not take her illness seriously. A fellow patient suggests that minimizing the danger may be Sergei’s way of defending himself against the possibility of losing her. The exchange does not settle what Sergei believes, but it shows how medication control and Emma’s suicide risk bear on the couple’s understanding of the illness as well as on the treatment plan.

Emma later asks Sergei to let her go, recognizing the burden of being regarded as a patient for whom others must take responsibility and protect from herself. She does not claim that things will simply improve; she tells him they will get worse again. This admission sits uneasily beside the hope invested in trying another medication. The trial offers a concrete clinical response to rapid cycling, while the narrative leaves its outcome open and presents living with recurring illness, rather than a sudden cure, as the condition in which treatment has to operate.